Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1452 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Xencor gets milestone payment from Boehringer Ingelheim

Xencor claims that a proprietary suite of XmAb Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation.

Lithera gets USPTO NOA for LIPO-102

LIPO-102 is Lithera’s novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 is currently under development for the treatment of